DUBLIN, Apr. 07, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/7wv4lh/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering.
The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019
According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.
Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market.
According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years.
Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance.
Key Vendors
- Actavis PLC
- Amgen Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd
- Sanofi
Other Prominent Vendors
- Abbott Laboratories
- Akebia Therapeutics
- AMAG Pharmaceuticals
- Cara Therapeutics
- FibroGen
- Keryx Biopharmaceuticals
- Reata Pharmaceuticals
- OPKO Health
- Pharmacosmos
- Raptor Pharmaceuticals
- Regulus Therapeutics
- Rockwell Medical
- Shield Therapeutics
- Takeda Pharmaceuticals
- Vifor Pharma Ltd
- Xenetic Biosciences
- ZS Pharma
For more information visit http://www.researchandmarkets.com/research/7wv4lh/global_chronic
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
